ClinicalTrials.gg
RecruitingNCT05717153Updated Nov 4, 2026

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

An Early Phase 1 interventional study of Biospecimen Collection and Computed Tomography in Diffuse Glioma and Malignant Glioma, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Mayo Clinic · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.
Updated Nov 4, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Glioma by Mayo Clinic — 8 open to participants now, 9 under way, none of them phase 3. Glioma · Mayo Clinic.

Planned enrollment
13th of 17
18 · median 28
Started
2023
with 1 other
Phase 1
7 of 20
3 open now
Registered
13th of 20
by date

Among the 20 studies in Glioma by Mayo Clinic, this one is the 13th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 13th registered.

Glioma

1,456 studies on the registry are indexed under Glioma; 351 are open to participants now.

Browse Glioma studies →

Open to participants now

8 of the 20 studies in Glioma by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 57 (21%) stop at 75 or younger; 63 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Glioma by Mayo Clinic, or all of them as a file.
02

Study summary

This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.

Read the detailed description

PRIMARY OBJECTIVE:

I. Determine how polyamine depletion impacts extracellular guanidinoacetate abundance.

SECONDARY OBJECTIVES:

I. Determine the impact of polyamine depletion on polyamine abundance and the global extracellular metabolome within live human gliomas, in situ.

II. Assess the feasibility of longitudinal microdialysis to evaluate pharmacodynamic responses of in situ gliomas to therapeutic intervention in a post-operative setting.

III. Assess the central nervous system (CNS) pharmacokinetics of DFMO and AMXT 1501.

IV. Adverse effects of study drugs in the immediate postoperative setting during microdialysis.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: Patients undergo surgical resection with magnetic resonance imaging (MRI) and placement of catheters for microdialysis at baseline. Patients receive DFMO orally (PO) in combination with AMXT 1501 PO on days 1-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection as well as undergo computed tomography (CT) and collection of blood on study.

ARM II: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO and AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

ARM III: Patients undergo surgical resection with MRI and placement of catheters for microdialysis at baseline. Patients receive DFMO PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery in the absence of disease progression or unacceptable toxicity. Patients also continue microdialysate collection, as well as undergo CT and collection of blood on study.

03

Conditions studied

  • Diffuse Glioma
  • Malignant Glioma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • Clinical and radiographic evidence suggesting a diagnosis of a diffuse high grade glioma (HGG), or a prior diagnosis of a diffuse glioma
  • Planned subtotal resection or due to tumor location, size, or other clinical indication deemed appropriate by the surgeon
  • Provide written for the current study and the Neuro-Oncology biorepository for archiving of cerebrospinal fluid (CSF) and blood samples collected on this protocol. Willing to remain in the hospital at Mayo Clinic (Rochester, MN) for three days added to their standard post-operative stay to undergo longitudinal microdialysis
  • (ANC) >= 1.5 x 10\^9/L without transfusion within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
  • >= 100 x 10\^9/L, without transfusion within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
  • >= 9 g/dL, without transfusion support within 7 days preceding the lab assessment (obtained =\< 14 days prior to registration)
  • or partial thromboplastin time (aPTT or PTT) =\< 1.5 x (ULN) (obtained =\< 14 days prior to registration)
  • (AST) and alanine aminotransferase (ALT) =\< 2.5 x ULN (obtained =\< 14 days prior to registration)
  • Total serum =\< 1.5 x ULN (obtained =\< 14 days prior to registration)
  • The patient is clinically euthyroid [Thyroid Stimulating Hormone (TSH)]
  • Serum creatinine =\< 1.5 x ULN or >= 60 mL/min/1.73 m\^2 for patients with serum creatinine levels above 1.5 x ULN (obtained =\< 14 days prior to registration)
  • Negative serum or urine pregnancy test is required for female subjects of childbearing age \< 14 days prior to registration

Exclusion criteria

Exclusion Criteria:

  • Inappropriate surgical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings
  • Vulnerable populations: pregnant or nursing women, prisoners, mentally handicapped
  • Unable to swallow tablets or who are at risk for impaired absorption of oral medication. NOTE: This includes but not limited to, vomiting, gastric resection/bypass, and duodenal/jejunal resection
  • Known or allergy to DFMO or AMXT 1501
  • to MRI or administration of gadolinium
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Arm I (MRI, resection, DFMO, AMXT 1501)

    Patients undergo magnetic resonance imaging (MRI) and surgical resection at baseline. Patients receive eflornithine PO in combination with AMXT 1501 PO on days 1-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Eflornithine · Procedure: Magnetic Resonance Imaging · Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate · Procedure: Resection · Device: Microdialysis · Procedure: Placement

  • Placebo comparator
    Arm II (MRI, resection, placebo, DMFO, AMXT 1501)

    Patients undergo magnetic MRI and surgical resection at baseline. Patients receive placebo PO on days 1 and 2 post-surgery, and then receive eflornithine PO and AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Eflornithine · Procedure: Magnetic Resonance Imaging · Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate · Procedure: Resection · Device: Microdialysis · Procedure: Placement

  • Active comparator
    Arm III (MRI, resection, DMFO, AMXT 1501)

    Patients undergo magnetic MRI and surgical resection at baseline. Patients receive eflornithine PO alone on days 1 and 2 post-surgery, then receive eflornithine PO in combination with AMXT 1501 PO on days 3-5 post-surgery. Patients also undergo CT after surgery and collection of blood on study.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Eflornithine · Procedure: Magnetic Resonance Imaging · Drug: Polyamine Transport Inhibitor AMXT-1501 Dicaprate · Procedure: Resection · Device: Microdialysis · Procedure: Placement

Interventions

  • ProcedureBiospecimen Collection

    Undergo collection of blood

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography

  • Given PO

    Also known as: Alpha-Difluoromethylornithine, DFMO, Difluoromethylornithine, Difluromethylornithine

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

  • DrugPolyamine Transport Inhibitor AMXT-1501 Dicaprate

    Given PO

    Also known as: AMX 513 Dicaprate, AMX513 Dicaprate, AMXT 1501 Dicaprate, AMXT-1501 Dicaprate

  • ProcedureResection

    Undergo surgical resection

    Also known as: Surgical Resection

  • DeviceMicrodialysis

    Undergo Microdialysis

  • ProcedurePlacement

    Undergo placement of catheters

    Also known as: Place

06

What researchers measure

Primary outcomes

  1. Change in the tumor/brain extracellular guanidinoacetate ratio

    Targeted metabolomics will be performed using the microdialysate aliquot collected at each time point to quantify guanidinoacetate content. Fold change values will be calculated between each time point within a patient. Fold changes values between time points will be compared across the three arms for statistically significant differences using a Wilcoxon signed rank test; p \< 0.05 will be considered statistically significant.

    Time frame: Baseline up to 2 months

Secondary outcomes

  1. Measured extracellular levels of glutamate in tumor and brain microdialysates

    Targeted metabolomics will be performed for each time point's microdialysate, assaying for polyamines (putrescine, spermine, and spermidine), in addition to ornithine and glutamate. Fold change values will be calculated between each time point within a patient. Fold changes values between time points will be compared across the three arms for statistically significant differences using a Wilcoxon signed rank test; p \< 0.05 will be considered statistically significant.

    Time frame: Up to 2 months

  2. Proportion of longitudinal microdialysis aliquots containing > 30 uL of microdialysate

    Targeted metabolomics will be performed for each time point's microdialysate, assaying for polyamines (putrescine, spermine, and spermidine), in addition to ornithine and glutamate. Fold change values will be calculated between each time point within a patient. Fold changes values between time points will be compared across the three arms for statistically significant differences using a Wilcoxon signed rank test; p \< 0.05 will be considered statistically significant.

    Time frame: Up to post-operative day 5

  3. Central nervous system free drug levels from microdialysate - DFMO

    Drug levels of difluoromethylornithine (eflornithine \[DFMO\]) at each time point will be calculated for pharmacokinetic analyses by Aminex Therapeutics to determine time of peak concentration (hr), maximum drug concentration (ng/mL), and area under the curve 0-t (hr\*ng/mL).

    Time frame: Up to 2 months

  4. Central nervous system free drug levels from microdialysate - AMXT 1501

    Polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) at each time point will be calculated for pharmacokinetic analyses by Aminex Therapeutics to determine time of peak concentration (hr), maximum drug concentration (ng/mL), and area under the curve 0-t (hr\*ng/mL).

    Time frame: Up to 2 months

  5. AMXT 1501 brain/plasma ratio over time

    Will be assessed via longitudinal microdialysis to understand how AMXT 1501 is distributed in Central Nervous System (CNS) tissue with and without tumor as compared to plasma levels over time.

    Time frame: Up to 2 months

  6. Incidence of adverse events

    Although no significant additional risks are anticipated in the proposed context, safety data will be assessed to evaluate for any unanticipated adverse events.

    Time frame: Up to 2 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Feb 2028, 53 months after the start.

Of 166 non-industry phase 1 interventional studies under Glioma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 53 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Oct 2023 → Sep 2023, primary completion Jan 2027 → Feb 2028 and completion Sep 2027 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2023
First posted
Feb 8, 2023
StartActual
Sep 15, 2023was Oct 2023
Primary completionEst.
Feb 29, 2028was Jan 2027
CompletionEst.
Feb 29, 2028was Sep 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2023→Sep 15, 2023
Nov 4, 2026
Primary completion
Jan 15, 2027→Feb 29, 2028
Nov 4, 2026
Study completion
Sep 15, 2027→Feb 29, 2028
Nov 4, 2026
Contact
Study contact changed: added •••5673. See the current contact
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mayo Clinic in Rochester · Rochester, United StatesContact added •••5673
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Oct 1, 2023→Sep 15, 2023
    Primary completion Jan 15, 2027→Feb 29, 2028
    Study completion Sep 15, 2027→Feb 29, 2028
    Contact Study contact changed: added •••5673. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic in Rochester · Rochester, United StatesContact added •••5673
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05717153
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Sep 15, 2023
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Neurosurgery Study Team
Contact
507-422-5673
Terence C. Burns, MD, PhD
principal investigator · Mayo Clinic in Rochester

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eflornithine

Start the discussion